![]() ![]() So subscribers get quite a diverse set of recommendations. ![]() In contrast, others (like the Growth portfolio) contain opportunities to help you grow the value of your portfolio. Some portfolios are set up specifically to help subscribers earn income (like the Income and Maximum Income for Retirees portfolios). Here are the five investment portfolios as of writing: You also get new investment recommendations from Jim Fink and the team over at Investing Daily and updates to the existing recommendations within the model portfolios.Īll in all, there are five model portfolios inside the member’s area, and each caters to a different type of investor with different investing goals and risk tolerances. Personal Finance is the flagship investment newsletter of Investing Daily, a popular investment education company, and it’s headed up by investing guru Jim Fink.Īccording to the Investing Daily website, the core focus of the service is on “safe, highly profitable investments that the mainstream herd hasn’t caught on to yet.”Īs a subscriber of Personal Finance, you get a new newsletter issue every month that contains a detailed breakdown of major market trends and emerging investments. ![]() Scopio also has a CE mark for its Full-Field Bone Marrow Aspirate Application on both devices.Recommended: Go here to see my #1 recommended stock advisory service Overview of Jim Fink’s Personal Finance That application is FDA-cleared and has a CE mark for the Scopio X100 and X100HT. Scopio said the Full-Field Peripheral Blood Smear Application, for example, can reduce peripheral blood smear review turnaround time by 60 percent. Scopio’s technology can also automate slide preparation, loading and processing. Once it’s digitized, the sample can be viewed for analysis by hematopathologists and other lab professionals remotely, not just by whoever’s near enough to peer into a microscope. The AI-powered system scans the sample and locates, annotates and presents images of blood cells at 100X resolution, flagging anomalies and suggesting classifications for review and confirmation. When a lab runs a patient sample on a hematology analyzer and finds abnormalities or need for analysis, the Scopio imaging platform can digitize a blood smear. The Scopio systems examine blood cell samples digitally, which allows for remote analysis with AI-powered decision support for faster results. “This partnership will help accelerate digital workflow transformation in hematology laboratories worldwide to enhance clinical decisions for optimal patient care.” How Scopio’s telehematology technology works “With Siemens Healthineers’ strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of hematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio.” Scopio Labs co-founder and CEO Itai Hayut said in a news release. It’s the third-largest medical device company in the world, according to our 2022 Medtech Big 100 ranking by revenue.īut it’s not the first major partnership for Scopio, which teamed up with Beckman Coulter last year after securing its latest FDA clearance. Siemens Healthineers is one of the biggest allies a medtech developer could ask for. “By offering laboratorians access to novel digital hematology technologies in one of the lab’s busiest testing disciplines, we will be providing critical tools to optimize operational workflow and laboratory efficiency, accelerate diagnosis, and improve patient care while addressing reduced resource capacity,” she said in a news release. Siemens Healthineers Head of Diagnostics Sharon Bracken called the deal “a step forward in delivering automated and digitized solutions that would redefine hematology workflow.” Siemens said those full-field digital cell morphology technology systems will complement its own Atellica HEMA 570 and Atellica HEMA 580 analyzers to give labs “high-resolution, full-field viewing for peripheral blood specimens and artificial intelligence-based morphological analysis with remote capabilities through the secure hospital network.” Scopio and Siemens Healthineers today announced a global distribution deal for the Scopio X100 and Scopio X100HT. Scopio Labs has enlisted a huge partner to get its telehematology technology into more labs. Scopio’s partnership with Siemens Healthineers will “accelerate digital workflow transformation in hematology laboratories worldwide,” Scopio CEO Itai Hayut said. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |